Bladder Cancer Treatment with Ultrasound and Nanobubbles

Technology Readiness Level: 3
  • Technology Readiness Level: 3

Abstract

Bladder cancer is the fourth most common cancer in men and the tenth most common in women. After initial surgical treatment, approximately 70 percent of patients with early stage non-muscle invasive bladder cancer (NMIBC) experience disease recurrence. The inability for oxygen to reach the tissues has been shown to contribute to chemoresistance, radioresistence, alteration of vasculature, chaotic blood flow, and genomic instability. There is a need for bladder cancer treatments with minimal side effects and with little to no tumor recurrence.

Researchers at Purdue University have developed a bladder cancer treatment which uses ultrasound-guided drug delivery. The use of oxygen-encapsulated cellulosic nanobubbles make it possible to reverse the hypoxia, decreasing the likelihood of tumor recurrence. Additionally, the use of an ultrasound beam for directing the oxygenated nanobubbles has shown to increase the efficiency of chemotherapy. This method has shown to decrease the amount of needed chemotherapeutic drug by 50 percent.

Website

https://prf.flintbox.com/technologies/D02F690B046D4EDCB2909BBFBD992D51

Advantages

  • Precise
  • Multimodal
  • Eliminating hypoxia
  • Minimal side effects
  • Less tumor recurrence

Potential Applications

  • Cancer treatment
  • Oxygen delivery
  • Eliminating hypoxia

Contact Information

Name: Patrick W Finnerty

Email: pwfinnerty@prf.org

Phone: 765-269-4080